Nionyx Bio

Nionyx Bio is a private, early-stage biotechnology company developing kidney-targeted AAV gene therapies for inherited and other serious renal diseases. The company is building a proprietary platform that combines engineered AAV capsids, gene cassette design, and delivery optimization to enable precise, one-time therapies with improved safety and scalability. Its approach is centered on tissue-targeted delivery to the kidney, an area that has historically been difficult for gene therapy. Nionyx also describes its Kidney Atlas as a reference library to support kidney tropism and translational vector design. The company launched publicly in 2025 with seed financing and is advancing a preclinical renal gene therapy pipeline.